Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 12, 2021 at 04:10 pm EDT
Share
Trevi Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 9.167 million compared to USD 7.413 million a year ago. Net loss was USD 9.794 million compared to USD 7.384 million a year ago. For the half year, operating loss was USD 17.256 million compared to USD 16.052 million a year ago. Net loss was USD 18.165 million compared to USD 15.857 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 0.41 a year ago. Basic loss per share from continuing operations was USD 0.92 compared to USD 0.89 a year ago.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
TREVI THERAPEUTICS, INC. 
